USpharma

USpharma is a privately held, commercial-stage pharmaceutical company focused on developing, manufacturing, licensing, and commercializing consumer health and prescription products. The company markets branded and pharmaceutically equivalent products across OTC and Rx categories, with particular emphasis on novel patient-friendly dosage forms such as soft chewables, gummies, modified-release products, and transdermal systems. USpharma operates a U.S.-based cGMP manufacturing campus in Miami Lakes, Florida and also highlights capabilities in analytical, R&D, and controlled-substance-related facilities through affiliated operations in Pennsylvania, Missouri, and India. Its business model appears to combine in-house product development, manufacturing, licensing, and commercialization rather than discovery-stage therapeutics. The company received growth capital from 1315 Capital in 2025 to expand commercialization, pipeline development, and operating scale.